Design and characterization of non-phosphopeptide inhibitors for Src family SH2 domains

被引:12
|
作者
Park, SH
Won, J
Lee, KH
机构
[1] Inha Univ, Dept Chem, Inchon 402751, South Korea
[2] Mogam Biotechnol Res Inst, Signal Transduct Lab, Yongin 449910, Kyunggi Do, South Korea
关键词
D O I
10.1016/S0960-894X(02)00523-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The development of novel non-phosphopeptide inhibitors for the Src family SH2 domain is described. Several commercially available hydroxyl aromatic acids have been appended off the N-terminus of pYEEIE and the potent phosphopeptide inhibitors of GST-Lck-SH2 were identified via ELISA. The most potent inhibitor, caffeic acid-pYEEIE, exhibited approximately 30-fold more binding activity than Ac-pYEEIE. Non-phosphopeptides were synthesized by replacing phosphotyrosine of caffeic acid-pYEEIE with tyrosine or 3,4-dihydroxyphenylalanine (DOPA). Caffeic acid-DOPA-EEIE that did not contain phosphotyrosine and its isosteres exhibited less than 20 times decreased binding affinity for GST-Lck-SH2 than Ac-pYEEIE. Moreover, it had a similar binding affinity for the GST-Lck-SH2, GST-Src-SH2, and GST-Fyn-SH2 domains. This study showed that the pY-1 positions of the phosphopeptide inhibitors and of the non-phosphopeptide inhibitors played an important role in the binding for the SH2 domain and that the non-phosphopeptide inhibitor must be a new lead in the development of SH2 inhibitors. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:2711 / 2714
页数:4
相关论文
共 50 条
  • [1] Predicting phosphopeptide selectivity of SH2 domains
    Sheinerman, FB
    Al-Lazikani, B
    Honig, B
    BIOPHYSICAL JOURNAL, 2001, 80 (01) : 333A - 333A
  • [2] THE SH2 DOMAINS OF SRC FAMILY KINASES ASSOCIATE WITH SYK
    AOKI, Y
    KIM, YT
    STILLWELL, R
    KIM, TJ
    PILLAI, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (26) : 15658 - 15663
  • [3] Covalent binding of catechols to Src family SH2 domains
    Jagoe, CT
    Kreifels, SE
    Li, JM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (02) : 113 - 116
  • [4] SH2 DOMAINS RECOGNIZE SPECIFIC PHOSPHOPEPTIDE SEQUENCES
    ZHOU, SY
    SHOELSON, SE
    CHAUDHURI, M
    GISH, G
    PAWSON, T
    HASER, WG
    KING, F
    ROBERTS, T
    RATNOFSKY, S
    LECHLEIDER, RJ
    NEEL, BG
    BIRGE, RB
    FAJARDO, JE
    CHOU, MM
    HANAFUSA, H
    SCHAFFHAUSEN, B
    CANTLEY, LC
    CELL, 1993, 72 (05) : 767 - 778
  • [5] Design of tetrapeptide ligands as inhibitors of the Src SH2 domain
    Nam, NH
    Pitts, RL
    Sun, GQ
    Sardari, S
    Tiemo, A
    Xie, MX
    Yan, BF
    Parang, K
    BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (04) : 779 - 787
  • [6] Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains
    Sperl, Bianca
    Seifert, Markus H. J.
    Berg, Thorsten
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (12) : 3305 - 3309
  • [7] Semisynthetic Src SH2 Domains Demonstrate Altered Phosphopeptide Specificity Induced by Incorporation of Unnatural Lysine Derivatives
    Virdee, Satpal
    Macmillan, Derek
    Waksman, Gabriel
    CHEMISTRY & BIOLOGY, 2010, 17 (03): : 274 - 284
  • [8] Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains
    Sheinerman, FB
    Al-Lazikani, B
    Honig, B
    JOURNAL OF MOLECULAR BIOLOGY, 2003, 334 (04) : 823 - 841
  • [9] Progress in the development of inhibitors of SH2 domains
    Cody, WL
    Lin, ZW
    Panek, RL
    Rose, DW
    Rubin, JR
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (01) : 59 - 98
  • [10] Identification and characterization of a large family of superbinding bacterial SH2 domains
    Kaneko, Tomonori
    Stogios, Peter J.
    Ruan, Xiang
    Voss, Courtney
    Evdokimova, Elena
    Skarina, Tatiana
    Chung, Amy
    Liu, Xiaoling
    Li, Lei
    Savchenko, Alexei
    Ensminger, Alexander W.
    Li, Shawn S. -C.
    NATURE COMMUNICATIONS, 2018, 9